New developments in the management of COPD: clinical utility of indacaterol 75 μg

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPD Updated2013 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdfAccessed July 8, 2013
   Google Scholar
• ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526
   PubMed Web of Science ®Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44217132052
   PubMed Web of Science ®Google Scholar
• HananiaNAMarciniukDDA unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory SocietyChest2011140356556621896511
   PubMed Web of Science ®Google Scholar
• MaltaisFDennisNChanCKRationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPDCOPD20131017910323272663
   PubMedGoogle Scholar
• GeitonaMHatzikouMSteiropoulosPAlexopoulosECBourosDThe cost of COPD exacerbations: a university hospital-based study in GreeceRespir Med2011105340240920970310
   PubMed Web of Science ®Google Scholar
• MahlerDAThe effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary diseaseJ Allergy Clin Immunol2002110Suppl 6S298S30312464939
   PubMedGoogle Scholar
• AnthonisenNRSkeansMAWiseRAManfredaJKannerREConnettJEThe effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trialAnn Intern Med2005142423323915710956
   PubMed Web of Science ®Google Scholar
• NaunheimKSWoodDEMohsenifarZLong-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research GroupAnn Thorac Surg200682243144316888872
   PubMed Web of Science ®Google Scholar
• SteiropoulosPTzouvelekisABourosDFormoterol in the management of chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20083220521518686730
   PubMedGoogle Scholar
• ChowdhuryBASeymourSMMicheleTMDurmowiczAGLiuDRosebraughCJThe risks and benefits of indacaterol – the FDA’s reviewN Engl J Med2011365242247224922168640
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
   PubMed Web of Science ®Google Scholar
• RoigJHernandoRMoraRIndacaterol, a novel once daily inhaled beta2-adrenoreceptor agonistOpen Respir Med J20093273019452036
   PubMedGoogle Scholar
• SteiropoulosPPapanasNNenaEBourosDIndacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary diseaseExpert Opin Pharmacother20121371015102922471750
   PubMed Web of Science ®Google Scholar
• HanJDaiLZhongNIndacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trialsBMC Pulm Med2013132623617268
   PubMed Web of Science ®Google Scholar
• FeldmanGJImproving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterolInt J Chron Obstruct Pulmon Dis20138899623431038
   PubMed Web of Science ®Google Scholar
• CopeSCapkun-NiggliGGaleREfficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparisonValue Health201215352453322583463
   PubMed Web of Science ®Google Scholar
• RodrigoGJNeffenHComparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic reviewChest201214251104111022383666
   PubMed Web of Science ®Google Scholar
• BattramCCharltonSJCuenoudBIn vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of actionJ Pharmacol Exp Ther2006317276277016434564
   PubMed Web of Science ®Google Scholar
• ScolaAMLoxhamMCharltonSJPeachellPTThe long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cellsBr J Pharmacol2009158126727619371332
   PubMed Web of Science ®Google Scholar
• NalineETrifilieffAFairhurstRAAdvenierCMolimardMEffect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchiEur Respir J200729357558117135231
   PubMed Web of Science ®Google Scholar
• SturtonRGTrifilieffANicholsonAGBarnesPJPharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slicesJ Pharmacol Exp Ther2008324127027517916760
   PubMed Web of Science ®Google Scholar
• PearlmanDSGreosLLaForceCOrevilloCJOwenRHigginsMBronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthmaAnn Allergy Asthma Immunol20081011909518681090
   PubMed Web of Science ®Google Scholar
• MagnussenHVerkindreCJackDIndacaterol once-daily is equally effective dosed in the evening or morning in COPDRespir Med2010104121869187620850959
   PubMed Web of Science ®Google Scholar
• LombardiDCuenoudBKramerSDLipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?Eur J Pharm Sci200938553354719819331
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLMateraMGβ(2) -adrenoceptor agonists: current and future directionBr J Pharmacol2011163141721232045
   PubMed Web of Science ®Google Scholar
• WestwoodMBourbeauJJonesPWCerulliACapkun-NiggliGWorthyGRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic reviewRespir Res2011124021477298
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951
   PubMed Web of Science ®Google Scholar
• KerwinEMGotfriedMHLawrenceDLassenCKramerBEfficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studiesClin Ther201133121974198422177371
   PubMed Web of Science ®Google Scholar
• BarnesPJPocockSJMagnussenHIntegrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless designPulm Pharmacol Ther201023316517120080201
   PubMed Web of Science ®Google Scholar
• CopeSZhangJWilliamsJJansenJPEfficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysisBMC Pulm Med2012122922732017
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLotvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• RenardDLoobyMKramerBLawrenceDMorrisDStanskiDRCharacterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesRespir Res2011125421518459
   PubMed Web of Science ®Google Scholar
• CopeSKraemerMZhangJCapkun-NiggliGJansenJPEfficacy of indacaterol 75 mug versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysisInt J Chron Obstruct Pulmon Dis2012741542022848154
   PubMed Web of Science ®Google Scholar
• WitekTJJrMahlerDAMeaningful effect size and patterns of response of the transition dyspnea indexJ Clin Epidemiol200356324825512725879
   PubMed Web of Science ®Google Scholar
• GotfriedMHKerwinEMLawrenceDLassenCKramerBEfficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studiesCOPD20129662963623020650
   PubMedGoogle Scholar
• JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory QuestionnaireAm Rev Respir Dis19921456132113271595997
   PubMed Web of Science ®Google Scholar
• KerwinEMWilliamsJIndacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspectiveTher Adv Respir Dis201371253723296242
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDKornmannOLawrenceDLassenCKramerBSafety of indacaterol in the treatment of patients with COPDInt J Chron Obstruct Pulmon Dis2011647749222003293
   PubMed Web of Science ®Google Scholar
• ChapmanKRRennardSIDograAOwenRLassenCKramerBLong-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928
   PubMed Web of Science ®Google Scholar
• RossiAPoleseGIndacaterol: a comprehensive reviewInt J Chron Obstruct Pulmon Dis2013835336323922496
   PubMed Web of Science ®Google Scholar
• PriceDGrayAGaleRCost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPDRespir Med2011105111635164721764277
   PubMed Web of Science ®Google Scholar
• PriceDAsukaiYAnanthapavanJMalcolmBRadwanAKeyzorIA UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource useAppl Health Econ Health Policy201311325927423529714
   PubMedGoogle Scholar
• RossiACentanniSCerveriIAcute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropiumRespir Med20121061849022035851
   PubMed Web of Science ®Google Scholar
• BeehKMWagnerFKhindriSDrollmannAFEffect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPDCOPD20118534034521793716
   PubMedGoogle Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• van NoordJABuhlRLaforceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax201065121086109120978028
   PubMed Web of Science ®Google Scholar
• WorthHChungKFFelserJMHuHRueeggPCardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPDRespir Med2011105457157921227674
   PubMed Web of Science ®Google Scholar